Northwest Therapies

Northwest Biotherapeutics is a clinical-stage biotechnology company focused on developing personalized immunotherapy products to treat various types of cancer. The company's proprietary DCVax platform utilizes a patient's own dendritic cells, which are educated to recognize and attack the full profile of antigens present in the patient's specific tumor. Its lead candidate, DCVax-L, has completed a large Phase 3 clinical trial for newly diagnosed and recurrent glioblastoma multiforme, demonstrating a significant extension in overall survival. Beyond brain cancer, the company is developing DCVax-Direct for inoperable solid tumors, which is currently in Phase 2 testing. Northwest Biotherapeutics operates with a focus on personalized medicine, aiming to provide more effective and less toxic alternatives to traditional cancer treatments. The company is currently navigating the regulatory submission process for DCVax-L in multiple jurisdictions, including the United Kingdom and the United States.